- Published at
- by investing.com
positive
positive
Repro Med Systems Stock Hits 52-Week High at $3.1 Amid Growth By Investing.com
Repro Med Systems Stock Hits 52-Week High at $3.1 Amid Growth
News for Repro Med Systems, Inc. (KRMD)
- Published at
- by prnewswire.com
mixedmixedNorth America Ambulatory Infusion Pumps Market Report 2022-2030: Home Infusion Therapies Gaining Momentum and Increase in Product Launches
/PRNewswire/ -- The "North America Ambulatory Infusion Pumps Market Size Analysis by Product Type, Route of Administration, Application, Distribution Channel -...- Published at
- by etfdailynews.com
positivepositiveRepro-Med Systems (OTCMKTS:REPR) Share Price Crosses Below 50 Day Moving Average of $2.44
Read Repro-Med Systems (OTCMKTS:REPR) Share Price Crosses Below 50 Day Moving Average of $2.44 at ETF Daily News- Published at
- by etfdailynews.com
positivepositiveRepro-Med Systems (OTCMKTS:REPR) Stock Price Passes Below Fifty Day Moving Average of $2.46
Read Repro-Med Systems (OTCMKTS:REPR) Stock Price Passes Below Fifty Day Moving Average of $2.46 at ETF Daily News- Published at
- by etfdailynews.com
positivepositiveRepro-Med Systems (OTCMKTS:REPR) Share Price Crosses Below 50-Day Moving Average of $2.50
Read Repro-Med Systems (OTCMKTS:REPR) Share Price Crosses Below 50-Day Moving Average of $2.50 at ETF Daily News- Published at
- by etfdailynews.com
positivepositiveRepro-Med Systems (OTCMKTS:REPR) Stock Passes Below 50-Day Moving Average of $2.51
Read Repro-Med Systems (OTCMKTS:REPR) Stock Passes Below 50-Day Moving Average of $2.51 at ETF Daily News- Published at
- by etfdailynews.com
positivepositiveRepro-Med Systems (OTCMKTS:REPR) Shares Pass Below Fifty Day Moving Average of $2.46
Read Repro-Med Systems (OTCMKTS:REPR) Shares Pass Below Fifty Day Moving Average of $2.46 at ETF Daily News- Published at
- by etfdailynews.com
positivepositiveAnalyzing Repro-Med Systems (OTCMKTS:REPR) & Nyxoah (NASDAQ:NYXH)
Read Analyzing Repro-Med Systems (OTCMKTS:REPR) & Nyxoah (NASDAQ:NYXH) at ETF Daily News- Published at
- by etfdailynews.com
positivepositiveKORU Medical Systems, Inc. (NASDAQ:KRMD) Sees Significant Decline in Short Interest
Read KORU Medical Systems, Inc. (NASDAQ:KRMD) Sees Significant Decline in Short Interest at ETF Daily News- Published at
- by etfdailynews.com
positivepositiveRepro-Med Systems (OTCMKTS:REPR) Share Price Crosses Above Fifty Day Moving Average of $2.33
Read Repro-Med Systems (OTCMKTS:REPR) Share Price Crosses Above Fifty Day Moving Average of $2.33 at ETF Daily News- Published at
- by insidermonkey.com
mixedmixed- Published at
- by benzinga.com
mixedmixedStocks That Hit 52-Week Lows On Friday
During Friday's morning session, 88 stocks hit new 52-week lows. Significant Points: The largest company in terms of market cap to set a ...- Published at
- by benzinga.com
mixedmixedThe Daily Biotech Pulse: Fulgent's Big Quarter, Gilead Awaits FDA Decision, Apellis Winds Up COVID-19 Study
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 4) ...RO.SWRHHBFOPNTOCULFLGT.MXFLGTDMTK.MXDMTKATRCACORA5I.F7F0.F7F0.BE0OT.F0OT.BEYMTXVYGR.MXVYGRVT6.SGVT6.FVRPXVLONVIVEVIRIV7B1.SGV7B1.FV7B1.BETLISTARASNSESGTXSANAQUREQLGNONYN.FONYN.BEONCYONCWFONCRONC.TOOLMANRBONLSPNEXINBTXMRNA.MXMRNALTIA.FLHDXLEGNKRMDKPTIIMRAIKTICPT.MXICPTI4P.MUI4P.FI4P.BEGLTOGIS.MUGIS.FGIS.DEGIS.BEGILD.MXGILD.MIGILDGHDN.SGGHDN.MUGHDN.FGHDN.BEEPZMEPE.FEPE.BEDYNDBTXBVSBCTXFBCTXBCT.VBCLIATNXASMBAPTOAPS.TOALBPS.PAAFIBADCT8IY.MU8IY.F8IY.BE8BTA.F7R9B.MU7R9B.F7R9B.BE6XB.F2MT.F25K.SG25K.MU25K.F25K.BE1KPA.MU1KPA.F1KPA.BE0QF.SG0QF.MU0QF.F0QF.BETAKFPRXAPLSAMGN.BAAMGNAMG.MUAMG.FAMG.DEAMG.BEABCL8QQ.HM8QQ.F8QQ.BE1JK.MU1JK.F1JK.BE- Published at
- by rttnews.com
mixedmixedAGIO's ACTIVATE-T Hits Goals, EDSA Catches Eye, JNJ Provides Rosy Outlook, VXRT On Watch
Today's Daily Dose brings you news about the progress of Vaxart's oral tablet COVID-19 vaccine candidate; Vir Biotech's phase I trial of VIR-3434 in chronic hepatitis B virus; Sorrento's COVID-19 program; Agios Pharma's phase III trial of Mitapivat and Johnson & Johnson's rosy outlook for 2021.